Milestone closes $75M royalty sale to RTW for etripamil US net sales

Milestone Pharmaceuticals Inc.

Closed sale of royalty interest under Royalty Purchase Agreement with RTW Royalty I DAC.
Received $75 million purchase price from funds managed by RTW.
Royalty interest is on annual net product sales of etripamil in the United States.
Previously disclosed on March 27, 2023; FDA approval of etripamil a condition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.